According to FutureWise analysis the market for postmenopausal vaginal atropy drugs in 2023 is US$ 2.32 billion, and is expected to reach US$ 4.21 billion by 2031 at a CAGR of 7.7%.
Postmenopausal Vaginal Atrophy Drugs are medications used to treat vaginal atrophy. This is a condition caused by the loss of estrogen in menopause. Dryness and itching can occur in women who have had their ovaries removed or are experiencing a decline in ovarian function. This can lead to incontinence or pain when having sex. Postmenopausal vaginal atrophies can be treated by increasing the levels of estrogen, a natural female hormone that helps protect and lubricate the vagina from infection and inflammation. This treatment also delays another issue that many women with postmenopausal vaginal atrophy face, known as Genitourinary Syndrome (GSM).
Premarin, a hormone therapy drug, replaces the estrogen naturally found in women. Premarin helps reduce the symptoms of menopause, such as hot flashes and vaginal dryness. This medication is effective in treating many conditions that are caused by low estrogen levels, such as osteoporosis and heart disease.
Vagifem, a medication that reduces the symptoms of menopause, such as vaginal dryness and burning, is used to treat the itching. It is a cream containing estradiol that can be absorbed by your vagina. Or, you can insert it into your vagina as a tablet/ring/patch to treat postmenopausal conditions like osteoporosis and heart disease.
Estrace is a medication that can be used to treat symptoms of menopause such as dryness, itching, and burning. You can apply it topically to the vagina, or you can take it orally by mouth. This is to treat conditions such as osteoporosis and heart disease caused by low estrogen levels after menopause.
Estring is a medication that helps to relieve menopausal symptoms. It restores the natural estrogen in the body. You can place it in your vagina to treat dryness, burning, or itching due to a lack of estrogen after menopause.
Femring, a ring that reduces hot flashes in menopause, also helps with other problems like night sweats and vaginal dryness. Estradiol is found in the femring ring and can be placed inside your vagina to relieve these symptoms, especially for postmenopausal women who experience vaginal atrophy.
Vaginal Gels are medicines that treat dryness, itching and burning. The gel restores the natural female hormone estrogen, which helps protect and lubricate the vagina from infection and inflammation. These gels can be applied externally to the vagina to treat these problems.
VVA (postmenopausal vaginal atrophy) refers to the drying out, thinning, and inflammation of the vagina. This can happen when estrogen is no longer being produced by women. It can cause painful sexual intercourse, painful bowel movements or urination, irritation of the vaginal area and even urinary tract infections. You can reduce symptoms by applying cream to the area.
Tablets are the most common way to use vaginal atrophy medications. Tablets have a fast release and high bioavailability. This means that the active medication can be easily absorbed into your body. Patients don't often need to take multiple pills at one time if they choose this delivery method. However, this quick release has its downsides. Some side effects can result, such as yeast infections or stomachaches.
You can also use the other vaginal atrophy drugs in patches such as Vagifem and Estring. All of these hormones work in the same way as the Premarin patch, but they are made differently so you may experience some differences. These patches diffuse through the body and reach their destination more steadily than pills.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Postmenopausal Vaginal Atropy Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Postmenopausal Vaginal Atropy Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.